Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia

Main Article Content

Baskaran Govindarajan Laura Willoughby Hamid Band Adam S Curatolo Emir Veledar Suephy Chen Michael Y Bonner Martin-Garrido Abel Marsha A Moses Jack L Arbiser

Abstract

Tuberous sclerosis (TS) is a common autosomal-dominant disorder characterized by tumors of the skin, lung, brain, and kidneys. Monotherapy with rapamycin however resulted in partial regression of tumors, implying the involvement of additional pathways. We have previously implicated platelet-derived growth factor-BB in TS-related tumorigenesis, thus providing a rationale for a combination of mTOR/PDGF blockade using rapamycin and imatinib. Here, we test this combination using a well-established preclinical model of cutaneous tumorigenesis in TS, tsc2ang1 cells derived from a skin tumor from a mouse heterozygous for tsc2. Treatment of tsc2ang1 cells with a combination of rapamycin and imatinib led to an inhibition of proliferation compared with either vehicle treatment or treatment with rapamycin or imatinib monotherapy. Combination therapy also led to a decrease in Akt activation. Potent in vivoactivity in animal experiments by combination therapy was noted, without toxicity to the animals. Our findings provide a rationale for the combined use of rapamycin and imatinib, both FDA approved drugs, for the treatment of TS.

Article Details

How to Cite
GOVINDARAJAN, Baskaran et al. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vascular Cell, [S.l.], v. 4, n. 1, p. 11, july 2012. ISSN 2045-824X. Available at: <https://vascularcell.com/index.php/vc/article/view/10.1186-2045-824X-4-11>. Date accessed: 20 jan. 2022. doi: http://dx.doi.org/10.1186/2045-824X-4-11.
Section
Original Research